GlaxoSmithKline to focus on subcutaneous ofatumumab research

GlaxoSmithKline is amending its joint research and development programme into the autoimmune treatment ofatumumab in order to focus on subcutaneous delivery of the drug.

In association with partner Genmab, the company will be ceasing development work on intravenous administration of the treatment in autoimmune indications, in order to commit more resources into what it believes to be a more convenient and tolerable method.

This decision is based on positive data from early-stage clinical trials, demonstrating ofatumumab's potential efficacy against multiple sclerosis, while the drug is also being tested as a treatment for rheumatoid arthritis.

The intravenous method of administration will continue to be researched in a number of oncology indications for the drug.

Dr Jan van de Winkel, president and chief executive officer of Genmab, said: "We are pleased and highly supportive of GlaxoSmithKline's continued commitment to the development of ofatumumab in these chronic diseases."

Last week, GlaxoSmithKline published data from a study of chronic obstructive pulmonary disease patients, providing new insight into the mechanisms which result in exacerbations of the illness.